Table 4

Association of neutralising capacity and anti-RBD-IgG concentration with MTX intake timing using linear regression analysis (n=64)*

	All patients†				Patients <60 years‡				Patients ≥60 years‡
	β	P value	95% CI	β_st	β	P value	95% CI	β_st	β	P value	95% CI	β_st
Neutralisation capacity
T_BV	0.00	0.976	−0.20 to 0.19	0.00	−0.05	0.749	−0.37 to 0.27	−0.06	0.04	0.807	−0.26 to 0.33	0.03
T_AV	0.19	0.005	0.06 to 0.32	0.30	0.09	0.301	−0.09 to 0.28	0.20	0.24	0.012	0.06 to 0.43	0.32
T_BV ≥10 days	−0.85	0.367	−2.73 to 1.02	−0.08	−0.36	0.789	−3.12 to 2.40	−0.05	−1.98	0.094	−4.31 to 0.35	−0.13
T_AV ≥10 days	2.00	0.008	0.53 to 3.47	0.27	−0.22	0.833	−2.34 to 1.91	−0.04	2.91	0.001	1.29 to 4.53	0.36
T_BV+T_AV	0.13	0.035	0.01 to 0.25	0.25	0.04	0.626	−0.13 to 0.22	0.11	0.18	0.039	0.01 to 0.35	0.29
Anti-RBD-IgG
T_BV	0.80	0.244	−0.56 to 2.15	0.09	0.47	0.575	−1.24 to 2.17	0.10	1.26	0.236	−0.86 to 3.39	0.12
T_AV	1.02	0.016	0.19 to 1.84	0.19	0.11	0.739	−0.56 to 0.78	0.04	1.63	0.036	0.12 to 3.14	0.22
T_BV ≥10 days	−1.86	0.777	−14.96 to 11.24	−0.02	0.49	0.950	−15.49 to 16.47	0.01	−6.43	0.323	−19.43 to 6.57	−0.05
T_AV ≥10 days	13.70	0.004	4.60 to 22.79	0.21	−2.53	0.583	−11.96 to 6.90	−0.07	20.03	0.005	6.57 to 33.50	0.26
T_BV+T_AV	0.95	0.003	0.33 to 1.58	0.22	0.21	0.487	−0.41 to 0.84	0.09	1.51	0.019	0.26 to 2.77	0.26

Significant results are in bold.
*One patient who did not hold MTX could not recall on which exact day MTX was taken and was therefore only considered for calculations of T_BV+T_AV (=7 days).
†Adjusted for female, age, MTX monotherapy, MTX+prednisolone, MTX combination±prednisolone, vaccine interval.
‡Adjusted for female, MTX monotherapy, MTX+prednisolone, MTX combination±prednisolone, vaccine interval. β (unstandardised beta-coefficient); β_st (standardised beta-coefficient); T_BV (time before vaccination), time between last MTX intake and vaccination; T_AV (time after vaccination), time between vaccination and re-intake of MTX; T_BV+T_AV, MTX interval at the time of vaccination.
MTX, methotrexate.